Lisata Therapeutics to Host Third Quarter 2022 Financial Results Conference Call on Thursday, November 10, 2022, at 4:30 p.m. Eastern Time
November 03 2022 - 8:00AM
Lisata Therapeutics, Inc. (Nasdaq: LSTA) (“Lisata” or the
“Company”), a clinical-stage pharmaceutical company developing
innovative therapies for the treatment of advanced solid tumors and
other serious diseases, today announced that the Company will
report its financial results for the three and nine months ended
September 30, 2022, on Thursday, November 10, 2022, at 4:30 p.m.
(ET).
The Company is utilizing a new conference call service. Those
wishing to participate must register for the conference call by way
of the following link: CLICK HERE TO REGISTER. Registered
participants will receive an email containing conference call
details for dial-in options. To avoid delays, we encourage
participants to dial into the conference call fifteen minutes ahead
of the scheduled start time.
A live webcast of the call will also be accessible under the
Investors & News section of the Company’s website and will be
available for replay beginning two hours after the conclusion of
the call for 12 months.
About Lisata Therapeutics
Lisata Therapeutics is a clinical-stage pharmaceutical company
dedicated to the discovery, development, and commercialization of
innovative therapies for the treatment of advanced solid tumors and
other major diseases. Lisata’s lead investigational product
candidate, LSTA1 (formerly known as CEND-1), is designed to modify
the tumor microenvironment by activating a novel uptake pathway
that allows anti-cancer drugs to penetrate solid tumors more
effectively. LSTA1 actuates an active transport system in a
tumor-specific manner, resulting in systemically co-administered
anti-cancer drugs more efficiently penetrating and accumulating in
the tumor, while normal tissues are not affected. LSTA1 has
demonstrated favorable safety, tolerability, and activity in
clinical trials to enhance delivery of standard-of-care
chemotherapy for pancreatic cancer. Lisata and its collaborators
have also amassed significant non-clinical data demonstrating
enhanced delivery of a range of emerging anti-cancer therapies,
including immunotherapies and RNA-based therapeutics. Lisata is
exploring the potential of LSTA1 to enable a variety of treatment
modalities to treat a range of solid tumors more effectively. In
addition, Lisata also has clinical development programs based on
its autologous CD34+ cell therapy technology platform. For more
information on the Company, please visit www.lisata.com.
Contact:
Investors and Media:
Lisata Therapeutics, Inc.John MendittoVice President, Investor
Relations and Corporate
CommunicationsPhone: 908-842-0084Email: jmenditto@lisata.com
Lisata Therapeutics (NASDAQ:LSTA)
Historical Stock Chart
From Aug 2024 to Sep 2024
Lisata Therapeutics (NASDAQ:LSTA)
Historical Stock Chart
From Sep 2023 to Sep 2024